Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?
Table 4
Univariable Cox proportional hazard analysis for HCC development.
Parameter
Univariable analysis
HR (95% CI)
value
Treatment
Combination group
1 (reference)
Single group
0.28 (0.01–6.38)
0.42
Age (per 1 year)
1.06 (0.98–1.15)
0.13
Male
2.21 (0.27–18.38)
0.46
HBeAg
Negative
1 (reference)
Positive
0.47 (0.10–2.10)
0.32
Underlying LC
Absent
1 (reference)
Present
4.91 (0.95–25.30)
0.06
AST (per 1 IU/L)
1.11 (1.07–1.16)
<0.001
ALT (per 1 IU/L)
1.04 (1.02–1.07)
0.002
rtA181 and rtN236 mutation
Absent
1 (reference)
Present
3.58 (0.53–23.92)
0.19
Virologic breakthrough
Absent
1 (reference)
Present
1.60 (0.07–38.00)
0.77
Minor virologic breakthrough
Absent
1 (reference)
Present
1.08 (0.16–7.32)
0.93
Time-varying Cox was applied for analysis. Virologic breakthrough was defined as HBV DNA . Minor virologic breakthrough was defined as HBV DNA . Univariable factors were analyzed with the Firth method. AST: aspartate aminotransferase; ALT: alanine aminotransferase; CI: confidence interval; HBV: hepatitis B virus; HR: hazard ratio; LC: liver cirrhosis.
